Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSHUA K SABARI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1356638894
CMS profile
1294108
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$163,853.72

125 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSHUA K SABARI

NPI 1356638894 · CMS profile ID 1294108

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356638894?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSHUA K SABARI, NPI 1356638894, CMS profile ID 1294108. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356638894?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOSHUA K SABARI, NPI 1356638894, CMS profile ID 1294108. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356638894?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOSHUA K SABARI, NPI 1356638894, CMS profile ID 1294108, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1356638894?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

125 matching records · $163,853.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 125 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 125.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $6,820.0007/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211313 CMS
Genentech USA, Inc. $109.0006/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133041473 CMS
Genentech USA, Inc. $1,515.0006/28/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133041477 CMS
Janssen Biotech, Inc. $2,100.0006/28/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078447511 CMS
AstraZeneca Pharmaceuticals LP $348.0006/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110532187 CMS
AstraZeneca Pharmaceuticals LP $56.2806/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110535804 CMS
AstraZeneca Pharmaceuticals LP $861.9206/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110546877 CMS
JAZZ PHARMACEUTICALS INC. $190.7306/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211317 CMS
JAZZ PHARMACEUTICALS INC. $150.0006/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211315 CMS
JAZZ PHARMACEUTICALS INC. $1,431.5206/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211373 CMS
JAZZ PHARMACEUTICALS INC. $2,480.0006/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211351 CMS
AstraZeneca Pharmaceuticals LP $14.7906/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110533750 CMS
AstraZeneca Pharmaceuticals LP $71.8506/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110550126 CMS
Daiichi Sankyo Inc. $31.2706/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089476969 CMS
Genentech USA, Inc. $46.4906/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133041469 CMS
JAZZ PHARMACEUTICALS INC. $57.6306/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211365 CMS
Janssen Biotech, Inc. $125.0405/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078447870 CMS
JAZZ PHARMACEUTICALS INC. $4,960.0005/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211341 CMS
JAZZ PHARMACEUTICALS INC. $229.5005/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211345 CMS
JAZZ PHARMACEUTICALS INC. $1,439.0005/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211361 CMS
JAZZ PHARMACEUTICALS INC. $1,368.9005/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211363 CMS
JAZZ PHARMACEUTICALS INC. $124.8905/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211343 CMS
JAZZ PHARMACEUTICALS INC. $605.2405/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211311 CMS
Mirati Therapeutics, Inc. $700.0005/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117170198 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $63.8905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117978018 CMS
AstraZeneca Pharmaceuticals LP $477.6205/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110552368 CMS
AstraZeneca Pharmaceuticals LP $1,370.0005/18/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126677418 CMS
Janssen Biotech, Inc. $3,500.0005/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078452189 CMS
AstraZeneca Pharmaceuticals LP $2,055.0005/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110548250 CMS
Gilead Sciences, Inc. $1,520.0005/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133599297 CMS
Janssen Biotech, Inc. $1,400.0005/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078446569 CMS
JAZZ PHARMACEUTICALS INC. $127.1105/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211347 CMS
JAZZ PHARMACEUTICALS INC. $127.1105/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211349 CMS
JAZZ PHARMACEUTICALS INC. $3,100.0004/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211353 CMS
AstraZeneca Pharmaceuticals LP $2,055.0004/23/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110534820 CMS
AstraZeneca Pharmaceuticals LP $63.4504/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126677964 CMS
AstraZeneca Pharmaceuticals LP $135.0004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110541245 CMS
Gilead Sciences, Inc. $133.9904/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133794673 CMS
Mirati Therapeutics, Inc. $700.0004/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117170203 CMS
Boehringer Ingelheim International GmbH $2,590.0004/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117978026 CMS
Janssen Scientific Affairs, LLC $33.7304/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078856004 CMS
JAZZ PHARMACEUTICALS INC. $3,720.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211329 CMS
JAZZ PHARMACEUTICALS INC. $5,580.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211335 CMS
AstraZeneca Pharmaceuticals LP $3,425.0003/31/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110552526 CMS
JAZZ PHARMACEUTICALS INC. $632.3503/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211357 CMS
JAZZ PHARMACEUTICALS INC. $1,400.7803/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211359 CMS
BeiGene, Ltd. $1,050.0003/27/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120865852 CMS
JAZZ PHARMACEUTICALS INC. $108.8003/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211337 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $44.7403/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117978016 CMS
JAZZ PHARMACEUTICALS INC. $13.8003/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150211339 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,074.84 12
PY2020 $49,337.09 24
PY2021 $58,159.65 26
PY2022 $123,416.76 81
PY2023 $197,901.09 160
PY2024 $163,853.72 125
PY2025 $154,263.08 112

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,214,121.14 94
PY2024 Principal investigator $2,487,242.40 90
PY2023 Principal investigator $1,300,896.53 158
PY2022 Recipient $477.67 2
PY2022 Principal investigator $984,089.57 113
PY2021 Principal investigator $953,202.96 94
PY2020 Principal investigator $288,582.39 34
PY2019 Principal investigator $661,080.71 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $49,405.70 12/23/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Phase I FIH study of BI 1810631 No dispute reported 06/30/2026 1220816640
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,672.00 12/05/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Phase I FIH study of BI 1810631 No dispute reported 06/30/2026 1220816638
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $647.06 12/05/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816706
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 12/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577568
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $266,047.77 11/30/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995494
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170,382.50 11/14/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Phase I FIH study of BI 1810631 No dispute reported 06/30/2026 1220816636
Principal investigator 1 Janssen Research & Development, LLC $3,060.00 11/07/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175312696
Principal investigator 1 Janssen Research & Development, LLC $3,060.00 11/07/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175312801
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 11/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577566
Principal investigator 1 Janssen Research & Development, LLC $4,928.00 10/09/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175312544
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 10/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577564
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $225,117.34 09/30/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995490
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $327,443.41 09/30/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995492
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $644.60 09/24/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995482
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $69.96 09/24/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995484
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $319.68 09/24/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995486
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $19.20 09/24/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995488
Principal investigator 1 Janssen Research & Development, LLC $4,928.00 09/15/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175313062
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,512.50 09/10/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816704
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $81,645.00 09/08/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816702
Principal investigator 1 Janssen Research & Development, LLC $13,300.00 09/08/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175312130
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $192,005.23 09/03/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Phase I FIH study of BI 1810631 No dispute reported 06/30/2026 1220816634
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 09/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577562
Principal investigator 1 Janssen Research & Development, LLC $7,702.00 09/01/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175311939
Principal investigator 1 Janssen Research & Development, LLC $5,805.00 09/01/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175312717
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,588.24 08/20/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Phase I FIH study of BI 1810631 No dispute reported 06/30/2026 1220816632
Principal investigator 1 Janssen Research & Development, LLC $1,651.00 08/18/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175312551
Principal investigator 1 Janssen Research & Development, LLC $16,086.00 08/18/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175313157
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 08/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577560
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $439.50 07/28/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995476
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $299.70 07/28/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995478
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $18.00 07/28/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995480
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,672.00 07/23/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816694
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,512.50 07/23/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816696
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,672.00 07/23/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816698
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $39,992.40 07/23/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816700
Principal investigator 1 Janssen Research & Development, LLC $2,725.00 07/22/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175313022
Principal investigator 1 Janssen Research & Development, LLC $260.00 07/09/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175312861
Principal investigator 1 Janssen Research & Development, LLC $2,096.00 07/07/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Multi Center Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies No dispute reported 06/30/2026 1175311773
Principal investigator 1 Janssen Research & Development, LLC $493.00 07/07/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175312431
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 07/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577558
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $54,104.00 07/01/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816692
Principal investigator 1 Janssen Research & Development, LLC $8,617.70 06/30/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions No dispute reported 06/30/2026 1175311850
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,150.75 06/27/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816688
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,102.95 06/27/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816690
Principal investigator 1 Janssen Research & Development, LLC $10,002.50 06/23/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1175312392
Principal investigator 1 Janssen Research & Development, LLC $6,638.00 06/23/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1175312755
Principal investigator 1 Janssen Research & Development, LLC $2,725.00 06/09/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175311897
Principal investigator 1 Janssen Research & Development, LLC $1,479.00 06/09/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175312654
Principal investigator 1 Janssen Research & Development, LLC $16,354.00 06/09/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions No dispute reported 06/30/2026 1175312971
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,491.40 06/05/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816684
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $338.00 06/05/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816686
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 06/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577556
Principal investigator 1 Janssen Research & Development, LLC $260.00 05/29/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175311810
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,672.00 05/28/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816678
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,703.40 05/28/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816680
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $243.00 05/28/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816682
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $498.10 05/27/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995466
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $244.86 05/27/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995468
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $339.66 05/27/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995470
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $26.60 05/27/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995472
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $12.00 05/27/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995474
Principal investigator 1 Janssen Research & Development, LLC $260.00 05/12/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175311803
Principal investigator 1 Mirati Therapeutics, Inc. $3,526.70 05/07/2025 Non-covered Recipient Entity
NYU Langone Hospitals - Tisch Hospitals Clinical Labs
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530881
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 05/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577554
Principal investigator 1 Janssen Research & Development, LLC $67,468.00 05/01/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175312772
Principal investigator 1 Eli Lilly and Company $49,664.00 04/22/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187886410
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,266.40 04/17/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816674
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $43,580.00 04/17/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816676
Principal investigator 1 Janssen Research & Development, LLC $3,550.00 04/03/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175311834
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 04/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577552
Principal investigator 1 Janssen Research & Development, LLC $6,137.00 03/31/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175311741
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $351.60 03/25/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995460
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $128.26 03/25/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995462
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 03/25/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995464
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 03/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577546
Principal investigator 1 Boehringer Ingelheim Espana S.A. $41.95 03/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577548
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $48,662.00 03/01/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816672
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $498.10 02/25/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995454
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $339.66 02/25/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995456
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $20.40 02/25/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995458
Principal investigator 1 Janssen Research & Development, LLC $1,285.20 02/24/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175312580
Principal investigator 1 Janssen Research & Development, LLC $1,794.00 02/20/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175312603
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,501.95 02/02/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816668
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,592.05 02/02/2025 Non-covered Recipient Entity
NYU School Of Medicine Office
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220816670
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 02/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577544
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $732.50 01/27/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995448
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $299.70 01/27/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995450
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $12.00 01/27/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220995452
Principal investigator 1 Eli Lilly and Company $6,723.25 01/27/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187884684
Principal investigator 1 Janssen Research & Development, LLC $11,557.00 01/20/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175312448
Principal investigator 1 Mirati Therapeutics, Inc. $22,375.40 01/15/2025 Non-covered Recipient Entity
NYU Langone Hospitals - Tisch Hospitals Clinical Labs
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530877
Principal investigator 1 Eli Lilly and Company $338,932.73 01/09/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A PHASE 1A/1B STUDY OF LY3537982 IN PATIENTS WITH KRAS G12C-MUTANT ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1187886408
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 01/01/2025 Non-covered Recipient Entity
NYU Langone Health
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577550